| Literature DB >> 35130301 |
Sabrina Yahiya1, Sarah Jordan1, Holly X Smith1, David C A Gaboriau2, Mufuliat T Famodimu1, Farah A Dahalan1, Alisje Churchyard1, George W Ashdown1, Jake Baum1.
Abstract
Formation of gametes in the malaria parasite occurs in the midgut of the mosquito and is critical to onward parasite transmission. Transformation of the male gametocyte into microgametes, called microgametogenesis, is an explosive cellular event and one of the fastest eukaryotic DNA replication events known. The transformation of one microgametocyte into eight flagellated microgametes requires reorganisation of the parasite cytoskeleton, replication of the 22.9 Mb genome, axoneme formation and host erythrocyte egress, all of which occur simultaneously in <20 minutes. Whilst high-resolution imaging has been a powerful tool for defining stages of microgametogenesis, it has largely been limited to fixed parasite samples, given the speed of the process and parasite photosensitivity. Here, we have developed a live-cell fluorescence imaging workflow that captures the entirety of microgametogenesis. Using the most virulent human malaria parasite, Plasmodium falciparum, our live-cell approach captured early microgametogenesis with three-dimensional imaging through time (4D imaging) and microgamete release with two-dimensional (2D) fluorescence microscopy. To minimise the phototoxic impact to parasites, acquisition was alternated between 4D fluorescence, brightfield and 2D fluorescence microscopy. Combining live-cell dyes specific for DNA, tubulin and the host erythrocyte membrane, 4D and 2D imaging together enables definition of the positioning of newly replicated and segregated DNA. This combined approach also shows the microtubular cytoskeleton, location of newly formed basal bodies, elongation of axonemes and morphological changes to the erythrocyte membrane, the latter including potential echinocytosis of the erythrocyte membrane prior to microgamete egress. Extending the utility of this approach, the phenotypic effects of known transmission-blocking inhibitors on microgametogenesis were confirmed. Additionally, the effects of bortezomib, an untested proteasomal inhibitor, revealed a clear block of DNA replication, full axoneme nucleation and elongation. Thus, as well as defining a framework for broadly investigating microgametogenesis, these data demonstrate the utility of using live imaging to validate potential targets for transmission-blocking antimalarial drug development.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35130301 PMCID: PMC8853644 DOI: 10.1371/journal.ppat.1010276
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 4Cellular phenotypes of PKG, CDPK4 and proteasome-inhibited parasites.
Cellular phenotypes upon inhibition of P. falciparum (A) CDPK4, (B) PKG and (C) proteasome by 1294, ML10 and bortezomib, respectively, during microgametogenesis. Perturbations to microtubule rearrangement (SiR-Tubulin, magenta), the host erythrocyte (WGA, green) and DNA replication (Vybrant DyeCycle Violet, blue) are shown as 2D maximum intensity projections of 3D data and alongside 3D sectioned views. Individual channels can be found in . (A) Failed DNA replication, cytoskeletal rearrangement and MTOC (white dashed line) transformation under 1294-treatment are shown. Stress induced egress prior to activation is also depicted. See for the corresponding time-lapse. (B) The failed DNA replication and cytoskeletal rearrangement due to PKG inhibition by ML10 is shown. Mixed egress phenotypes were observed, including (i) incomplete and (ii) failed egress. See corresponding timelapses in . (C) Perturbations to (i) MTOC transformation (white dashed line) and (ii-iii) formation of two-three truncated axonemes resulting from proteasome inhibition are shown. See S25, S27 and S28 Videos for the corresponding timelapses. (D) A continuum of SiR-tubulin labelling intensity (arbitrary units) in untreated (n = 4), 1294 (n = 3), ML10 (n = 3) and bortezomib (n = 6) treated parasites. (E) SiR-tubulin labelling (arbitrary units) at 10 minutes post-activation under different treatments. Untreated (n = 14), 1294 (n = 16), ML10 (n = 16), bortezomib (n = 9). Significance was calculated using one-way ANOVA tests with Tukey multiple comparisons (**** p < .0001). (F) Vybrant DyeCycle Violet labelling (arbitrary units) was significantly reduced (one-way ANOVA tests with Tukey multiple comparisons (**** p < .0001)) at 10 minutes post-activation under different treatments. Untreated (n = 17), 1294 (n = 15), ML10 (n = 9), bortezomib (n = 16). (G) A graph depicting the cell circularity and SiR-tubulin labelling intensity of individual cells across the entirety of microgametogenesis under varying treatments. Untreated (n = 188), 1294 (n = 58), ML10 (n = 106), bortezomib (n = 105). (H) Percentage egress at 10 minutes post-activation under different treatments was quantified, with distinct egress phenotypes depicted beside the stacked bar graph. Untreated (n = 58), 1294 (n = 20), ML10 (n = 25), bortezomib (n = 24). All imaging data depicted reflect observations from >3 biological replicates.